Phaseline

Companies › GCP-Service International West

GCP-Service International West: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Hematology, Cardiovascular; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RVU120 (SEL120)
CDK 8/19 inhibitor
CDKN2APhase 2Low Risk Myelodysplastic SyndromesMay 2027
Omegaven® (Fish Oil)
Intravenous fish oil emulsion providing long-chain n-3 polyunsaturated fatty acids (eicosa
–Phase 2Intensive Care UnitMar 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06243458RVU120 (SEL120)Phase 2Low Risk Myelodysplastic SyndromesHematologyMay 2027
NCT06279793Omegaven® (Fish Oil)Phase 2Intensive Care UnitCardiovascularMar 2030

Targets

CDKN2A (1)

Companies with the same targets

–

Companies built like this

AllRock Bio Nyrada Zomagen Biosciences Agiana Pharmaceuticals Cardurion Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.